Liquidity, Beta, and the Biotech Edge | Ep. 1038
Finding Alpha When the Herd Gets Whiplashed
Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we dive into the invisible forces shaping biotech investing in 2025. Liquidity, beta, and fund structure are no longer background noise, they’re driving outcomes. As the venture ecosystem unwinds a decade of excess, biotech investors face a rare moment: low M2, collapsing valuations, and a flood of uncorrelated science waiting to be backed. We’ll walk through why DPI is the new north star, how portfolio overlap masks risk, and what this reset means for the next generation of scientific value creation.
We are now publishing 7x per week according to the following cadence:
Mondays: Stocks
Tuesdays: Biotech
Wednesdays: Podcast
Thursdays: Markets
Fridays: News
Saturdays: Podcast
Sundays: Strategy
We are also publishing unique content on X - be sure to follow up if you are not already @BowTiedBiotech. And to check-out the archive of our work on X you can find it on our website at: BowtiedBiotech.subtack.com/x-articles.
SUBSCRIBE TO PODCAST HERE:
Please help spread the work by subscribing and hitting the share button if you are enjoying our bi-weekly newsletters!
Enough shilling for the day, lots to cover this week, let's get started!
Introduction
Zero-rate liquidity hid a dirty secret and nobody in the VC world admit this:
Most venture “alpha” was a leveraged bet on M2 expansion, not clairvoyant deal picking.
Now that money growth whiplashes, the market is discovering who converted paper marks into cash and who surfed a tide that has rolled back. Biotech investors (used to living at the sharp edge of science and capital) have a unique chance to profit from the reset. This essay maps the fault lines, shows where the cracks widen into opportunity, and hands you a playbook to capture the upside others still ignore.
